MOHD ABDULLAHA
University at Buffalo, State University of New York, Texas A&M University, AcsIR, Baylor College of Medicine
Research areas: Chemistry · Organic Chemistry · Synthesis and biological activity · Inflammasome and immune disorders · Cholinesterase and Neurodegenerative Diseases
About
Dr. Mohd Abdullaha is a medicinal chemist and postdoctoral researcher in the Department of Chemistry at the University at Buffalo, The State University of New York. His research focuses on the rational design, synthesis, and biological evaluation of small-molecule therapeutics for cancer, neurodegenerative diseases, and viral infections through an interdisciplinary approach integrating medicinal chemistry, chemical biology, molecular modeling, and drug discovery.
During his Ph.D., Dr. Abdullaha worked on the development of multi-target-directed ligands for Alzheimer's disease, with a particular emphasis on cholinesterase inhibition and modulation of the NLRP3 inflammasome. His subsequent postdoctoral research expanded to antiviral drug discovery, including the development of inhibitors targeting the SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro), as well as targeted protein degradation strategies using PROTAC technology. He also contributed to the design of cyclic organopeptides and CDK-targeting degraders.
His current research is focused on discovering first-in-class small molecules that target TFE3 fusion oncoproteins in translocation renal cell carcinoma (tRCC). His work combines structure-based drug design, synthetic medicinal chemistry, computational modeling, biophysical and cellular assays, and in vivo efficacy studies to identify novel therapeutic strategies for cancers driven by oncogenic transcription factors.
Dr. Abdullaha has authored peer-reviewed publications and book chapters and serves as a reviewer for leading journals in medicinal chemistry and drug discovery. His long-term research goal is to translate innovative chemical approaches into effective therapies for diseases with significant unmet medical needs.
Employment
-
University at Buffalo, State University of New York Postdoc Associate2024 - Present
-
Texas A&M University Postdoc Associate2024 - 2024
-
Baylor College of Medicine Postdoc Associate2022 - 2024
Education
-
AcsIR Ph.D2016 - 2021
Projects & Funding
Projects & funding information is unavailable.
Publications (12)
- Methoxy-naphthyl-Linked N-Benzyl Pyridinium Styryls as Dual Cholinesterase Inhibitors: Design, Synthesis, Biological Evaluation, and Structure–Activity Relationship Save
- Blood–brain barrier permeable benzylpiperidin‐4‐yl‐linked benzylamino benzamides as dual cholinesterase inhibitors Save
- Tetramethoxystilbene Inhibits NLRP3 Inflammasome Assembly via Blocking the Oligomerization of Apoptosis-Associated Speck-like Protein Containing Caspase Recruitment Domain: In Vitro and In Vivo Evaluation Save
- IIIM-941, a Stilbene Derivative Inhibits NLRP3 Inflammasome Activation by Inducing Autophagy Save
- Design, synthesis and comparative analysis of triphenyl-1,2,3-triazoles as anti-proliferative agents Save
- Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase Save
- Discovery of Helminthosporin, an Anthraquinone Isolated from Rumex abyssinicus Jacq as a Dual Cholinesterase Inhibitor Save
- Discovery of benzo[cd]indol-2-one and benzylidene-thiazolidine-2,4-dione as new classes of NLRP3 inflammasome inhibitors via ER-β structure based virtual screening Save
- Discovery of Quinazolin-4(3H)-ones as NLRP3 Inflammasome Inhibitors: Computational Design, Metal-Free Synthesis, and in Vitro Biological Evaluation Save
- Nonantioxidant Tetramethoxystilbene Abrogates α-Synuclein-Induced Yeast Cell Death but Not That Triggered by the Bax or βA4 Peptide Save
- Metal-Free Ionic-Liquid-Mediated Synthesis of Benzimidazoles and Quinazolin-4(3H)-ones from Benzylamines Save
- Oxidant-Controlled C-sp2/sp3–H Cross-Dehydrogenative Coupling of N-Heterocycles with Benzylamines Save